Showing 6531-6540 of 9554 results for "".
- Dr. Suneel Chilukuri Named Hydrinity Accelerated Skin Science’s Chief Medical Advisorhttps://practicaldermatology.com/news/dr-suneel-chilukuri-named-hydrinity-accelerated-skin-sciences-chief-medical-advisor/2461692/Suneel Chilukuri, MD, is Hydrinity Accelerated Skin Science’s new Chief Medical Advisor. In this role, Dr. Chilukuri will chair the Hydrinity Accelerated Skin Science Medical Advisory Board. He will aid product development as well as develop and oversee all clinica
- MRA Announces $6.3 Million in Grants to Advance Melanoma Preventionhttps://practicaldermatology.com/news/mra-announces-63-million-in-grants-to-advance-melanoma-prevention/2461691/The Melanoma Research Alliance (MRA) announced a new $6.3 million commitment to fund melanoma resear
- Opzelura Helps Beat AD Itchhttps://practicaldermatology.com/news/opzelura-helps-beat-ad-itch/2461690/Opzelura (ruxolitinib) cream 1.5% showed substantial and rapid itch reduction in patients with mild-moderate Atopic Dermatitis (AD). These data were featured in a poster presentation at the Revolutionizing Atopic Dermatitis (RAD) Conference, held from April 29-May 1 in Washing
- Lilly's Lebrikizumab Improves AD on Face, Handshttps://practicaldermatology.com/news/lillys-lebrikizumab-improves-ad-on-face-hands/2461689/Up to 73% of atopic dermatitis patients (AD) receiving lebrikizumab showed Improved or cleared skin on face or hands at 16 weeks, a new study shows. Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients 12 y
- Aquavit News: Company Files Investigational New Drug Application for Dermatoxhttps://practicaldermatology.com/news/aquavit-news-company-files-investigational-new-drug-application-for-dermatox/2461687/Aquavit has filed an Investigational New Drug Application with the U.S Food and Drug Administration (FDA) for Dermatox (aqubotulinumtoxinA), their intradermal injection of botulinum toxin. AqubotulinumtoxinA has already received regulatory approvals in Asia, Sou
- Galderma's Sculptra Now FDA Approved for Cheek Wrinkleshttps://practicaldermatology.com/news/galdermas-sculptra-now-fda-approved-for-cheeks/2461683/The U.S. Food and Drug Administration (FDA) has approved Sculptra (injectable poly-L-lactic acid (PLLA-SCA)) for the correction of fine lines and wrinkles in the cheek area. Sculptra is the first FDA-approved PLLA collagen stimulator that helps stimulate natural collagen production in the
- ASA Honors Dr. Mark G. Lebwohl, Leo Pharmahttps://practicaldermatology.com/news/asa-honors-dr-mark-g-lebwohl-leo-pharma/2461652/Mark G. Lebwohl, MD and LEO Pharma received honors at the American Skin Association’s (ASA) annual Spring Gala, "We were proud to honor Dr. Mark Lebwohl and LEO Pharma for their dedication to the field of dermatology. Both honorees share in ASA
- Dr. James G. Krueger Joins ASA’s Board of Directorshttps://practicaldermatology.com/news/dr-james-g-krueger-joins-asas-board-of-directors/2461651/James G. Krueger, MD, PhD, will join the American Skin Association’s (ASA) Board of Directors. Dr. Krueger is the David Martin Carter Professor in Clinical Investigation and Head of the Laboratory for Investigative Dermatology at The Rockefeller University in&
- First Patient Dosed in Phase 2 Trial of ADX-629 in ADhttps://practicaldermatology.com/news/first-patient-dosed-in-phase-2-trial-of-adx-629-in-ad/2461650/Aldeyra Therapeutics, Inc.
- Lupus Research Alliance Collaborates with the FDA to Launch Public-Private Partnershiphttps://practicaldermatology.com/news/lupus-research-alliance-collaborates-with-the-fda-to-launch-public-private-partnership/2461641/The Lupus Research Alliance (LRA) announced the launched of Lupus Accelerating Breakthroughs Consortium (Lupus ABC), a public-private partnership. The goal of the partnership is to bring people with lupus together in collaboration with the F